Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
New England Journal of Medicine2020Vol. 382(6), pp. 545–553
Citations Over TimeTop 1% of 2020 papers
Enli Liu, David Marín, Pinaki P. Banerjee, Homer A. Macapinlac, Philip A. Thompson, Rafet Başar, Lucila Nassif Kerbauy, Bethany Overman, Peter F. Thall, Mecit Kaplan, Vandana Nandivada, Indresh Kaur, Ana Karen Nunez Cortes, Kai Cao, May Daher, Chitra Hosing, Evan N. Cohen, Partow Kebriaei, Rohtesh S. Mehta, Sattva S. Neelapu, Yago Nieto, Michael Wang, William G. Wierda, Michael J. Keating, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani
Abstract
Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).
Related Papers
- → Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors(2020)2,047 cited
- → 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors(2015)1,752 cited
- → B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?(2022)20 cited
- → Distribution Measurements of Chimeric Antigen Receptor-Modified T Cells Against CD19(2020)
- → Anti-cd19-car-transduced-t-cells/chimeric-antigen-receptor-t-cell-therapeutics-shanghai-unicar-therapy-bio-medicine-technology(2019)